BofA analyst Craig Bijou downgraded Haemonetics (HAE) to Underperform from Neutral with a price target of $68, down from $95, after Q3 revenue missed and the company lowered FY25 organic growth guidance. The quarter likely adds to investor worries on the plasma market recovery and durability of Vascade growth, notes the analyst, who also expects tariffs to remain “somewhat of an overhang” as Haemonetics has higher exposure to Mexico and Canada.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio